|
Market Report
|
 Substance Dependence - Part I: Nicotine
The high prevalence of nicotine dependence, strong uptake of Pfizer's Chantix (varenicline), and the launch of new innovative therapies will cause the nicotine dependence prescription drug market to grow to $4.6 billion across the seven major markets by 2016. Innovative therapies are set to offer patients a convenient dosing regimen and thereby carrying the potential for improved compliance.
|
|
Read more...
|
|
|
Market Report
|
Orphan Diseases in CNS - Part I: Huntington's Disease
The current Huntington’s disease market is comprised of off-label prescriptions of psychotropic drugs. In the near term, two pipeline drugs are set to enter the market, demonstrating the viability of this disease as a primary marketing indication. In the longer term, with a strong genetic link and reliable diagnostic test, prophylactic treatment with a disease modifying drug could prove lucrative.
|
|
Read more...
|
|
|
Market Report
|
Head and Neck Cancer
Incidence of head and neck cancer across the seven major markets in 2007 is estimated to total 137,299. Forty percent of these cases present with stage III/IV disease, when patient prognosis is poor. Cisplatin-based therapy continues to dominate treatment, although the toxicities associated with this approach highlights the need for more tolerable alternatives, such as Erbitux.
|
|
Read more...
|
|
|
Market Report
|
Prostate Cancer - Hormone-refractory patients still waiting for treatment breakthroughs
Prostate cancer is one of the four most common tumor types, and is the most common cancer and second most common cause of cancer-related death to affect men. Prostate cancer is curable when localized and frequently responds to treatment at an advanced stage. The rate at which prostate tumors grow varies between patients, with some achieving prolonged survival even with metastatic disease.
|
|
Read more...
|
|
|
Market Report
|
Parkinson's Disease -Evidence of neuroprotection essential to progress treatment dynamics
Parkinson's disease (PD) is a progressive, degenerative condition of the central nervous system that affects the way the brain coordinates body movements, including walking, talking and writing. PD affects less than 1% of the population in the seven major markets (7MM); with patients typically being diagnosed in their early sixties and living for over 18 years after the onset of first symptoms.
|
|
Read more...
|
|
|
Market Report
|
Inflammatory Bowel Disease - Debate over early aggressive treatment continues
Inflammatory bowel disease (IBD) is a chronic inflammatory condition that affects the gastrointestinal tract causing a number of distressing symptoms such as bleeding, diarrhea and abdominal pain. IBD includes key subsets Crohn's disease and ulcerative colitis, both of which can significantly impact on the quality of life of an individual.
|
|
Read more...
|
|
|
Market Report
|
Endometriosis - Scientific clarity will unlock market potential
Endometriosis is a painful, menstrual-related disorder that is thought to affect approximately 10% of the female population of reproductive age. Despite this large patient potential, growth of the endometriosis market has been limited by low levels of investment, poor awareness among physicians and the public, problematic diagnosis, and lack of effective therapies.
|
|
Read more...
|
|
|
Market Report
|
Peripheral artery disease - Poor disease awareness hinders new agents
Peripheral artery disease, sometimes also referred to as peripheral vascular disease, is atherosclerosis in peripheral regions, which can lead to loss of blood flow to the limbs, and can result in loss of life, limb amputation and cardiovascular events. The current pharmacological treatment options are limited, and there are large unmet needs associated with the disease.
|
|
Read more...
|
|
|
Market Report
|
Substance Dependence - Part II: Alcohol
The continued uptake of existing brands and the launch of two opioid antagonists will cause the market to grow at a compound annual growth rate of 13.5% from 2006 to reach $304m across the seven major markets by 2016. The alcohol dependence market requires a paradigm shift away from the public perception that it is a behavioral disorder towards being regarded as a treatable medical condition.
|
|
Read more...
|
|
|
Market Report
|
Orphan Diseases in CNS - Part II: Amyotrophic Lateral Sclerosis
The ALS market was worth $148m in 2006 across the seven major markets. With the only approved treatment for ALS, Sanofi-Aventis's Rilutek (riluzole), facing generic incursion in 2012-13, future growth in this market is dependent on the success of pipeline drugs.
|
|
Read more...
|
|
|
Market Report
|
Myelodysplastic Syndromes - First approvals spur some interest in a niche market
Myelodysplastic syndromes (MDS) are a heterogeneous group of hematopoietic stem cell disorders. With a forecast incidence of 36,769 across the seven major markets in 2007, they are one of the most common hematological malignancies. Currently, the only potentially curative option is hematopoietic stem cell transplantation but this is only suitable for a small subset of patients.
|
|
Read more...
|
|
|
Product Report
|
|
HIV - Novel NNRTIs address crucial unmet need
Treatment of HIV has come a long way since the discovery of the virus. Although no real cure has been found yet, the last few decades have seen the introduction of many classes of drugs that suppress the replication of the virus. As therapeutics have improved dramatically in terms of efficacy, safety and convenience, the bar for new drugs has been raised considerably.
|
|
Read more...
|
|
|
Product Report
|
Non-Hodgkin's Lymphoma - Is there room to emulate Rituxan's success?
Non-Hodgkin's lymphoma (NHL) is the most common hematological malignancy and is comprised of around 30 different disease subtypes. Each of these present with a distinct set histological, genetic and clinical characteristics. Treatment options in NHL include chemotherapy, targeted therapies, stem cell transplantation and radiotherapy.
|
|
Read more...
|
|
|
Product Report
|
Multiple Myeloma - Exploring new targets for multiple drug therapy
The incidence of multiple myeloma is forecast to total 40,885 cases across the seven major pharmaceutical markets in 2007. Current drug therapy is planned around stem cell transplantation. The recent approval of three new agentsThalomid (thalidomide; Celgene), Revlimid (lenalidomide; Celgene) and Velcade (bortezomib; Millenium/Johnson & Johnson) has significantly advanced treatment.
|
|
Read more...
|
|
|
Market Report
|
Key trends and events in the 7 major markets
The generics market is growing, driven by rising healthcare costs and fed by a steady stream of patent expiries. Levels of generic uptake vary widely across the 7 major markets, with important implications for industry strategy.
|
|
Read more...
|
|
|
Market Report
|
Hepatitis C - Small-molecule antivirals pave the way for triple therapy
Research and Development activity in the Hepatitis C arena continue to be high. The market still holds many areas of unmet medical needs: while existing therapies provide good efficacy for about half of the patient population, side effects and limited efficacy in other patients offer much room for improvement. Several development setbacks over the past 18 months highlight the obstacles in R&D.
|
|
Read more...
|
|
|
Company Report
|
Combating Fake Pharmaceuticals
Counterfeit medicines are a global problem costing patient's their health and the pharmaceutical industry and governmental organizations millions of dollars per year. Although there is no one preventative strategy, there are several measures that can be employed simultaneously to reduce the risk of fake medicines entering the pharmaceutical supply chain.
|
|
Read more...
|
|
|
Company Report
|
Strategic Analysis of the Sales Outlook for Big Pharma, Mid Pharma, Japan Pharma and Biotech
Based on an analysis of 43 companies and 1,200+ products, Datamonitor forecasts that pharmaceutical industry ethical sales will increase at a modest 3.2% CAGR 2006 to 2012. However, behind this industry average figure there are strategic segments of the market that offer double-digit growth rates through barriers against generic competition and the opportunity for aggressive indication broadening.
|
|
Read more...
|
|
Farmavita.Net Journal 
